threo-1-(2-Methyl-3-phenyl-3-(4-trifluoromethylphenoxy)propyl)piperidine | 158546-02-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: threo-1-(2-Methyl-3-phenyl-3-(4-trifluoromethylphenoxy)propyl)piperidine
• 英文别名: 1-[2-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]piperidine
• CAS: 158546-02-2
• 化学式: C₂₂H₂₆F₃NO
• 分子量: 377.45
• InChiKey: QPYWEVNGPVCEHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  trans-1-(1-(4-Trifluoromethylphenoxy)indan-2-yl)methyl piperidine, hydrochloride 、 4-氟三氟甲苯 、 potassium tert-butylate 、 2-Methyl-3-piperidino-1-phenylpropanol 生成 threo-1-(2-Methyl-3-phenyl-3-(4-trifluoromethylphenoxy)propyl)piperidine
  参考文献：
  名称：

  Propanolamine derivatives, their preparation and use

  摘要：

  化合物的公式I，其中X是苯基，未取代或可选地取代一个或多个氰基，卤基，卤代烷基，C1-6-烷氧基，C1-6-烷基，C1-5-酰基，C3-5-烯基，芳氧基，芳基氧基，氨基，C1-6-烷基单取代或双取代氨基，C1-4-酰胺基，氨基甲酰基，C1-4-烷基N-单取代或双取代的氨基甲酰基，C1-4-烷基取代氨基，C1-2-烷基单取代或双取代氨基，N0₂，吗啉基或咪唑基；以及R是3,4-亚甲二氧基苯基，芳基或杂环芳基，所有这些都可以可选地取代一个或多个氰基，卤基，C1-6-烷基，C1-6-烷氧基，C2-6-烯基，三氟甲基，C3-5-亚烷基，芳基氧基，芳基氧基或C1-6-烷硫基；以及R¹和R²是C1-10-烷基，C3-7-环烷基，C2-10-烯基，C3-6-环烷基-C1-5-烷基，所有这些都可以未取代或取代C1-5-烷基，C1-5-烷氧基或氰基；或R¹和R²一起形成一个含有至少一个氮原子的5、6或7元环，或可选地含有两个氮原子，一个或两个氧原子或一个或两个硫原子或其组合，该环未取代或可选地取代C1-4-烷基，C1-4-烷氧基或芳基；以及R³、R⁴、R⁵、R⁶和R⁷分别是氢，C1-4-烷基或苯基；或者R⁴和X一起形成一个含有5或6个原子的碳环，或其与药学上可接受的酸的盐；但是，当X是取代有氰基，卤基，卤代烷基，C1-6-烷氧基，C1-6-烷基，C1-5-酰基，C3-5-亚烷基，芳氧基或芳基氧基时，R¹和R²不是C3-7-环烷基，C1-10-烷基或C2-10-烯基，可以是直链，支链或环状，未取代或取代有C1-4-烷氧基，芳氧基或环烷基，氰基或环烷基烷基。这些化合物在缺氧，创伤性损伤，缺血，偏头痛，癫痫，帕金森病，阿尔茨海默病和其他神经退行性疾病的治疗中是有用的。

  公开号：

  EP0576766A1

文献信息

• Propanolamine derivatives, their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0576766A1

  公开（公告）日：1994-01-05

  Compounds of formula I wherein X is phenyl unsubstituted or optionally substituted with one or more cyano, halogeno, halogenoalkyl, C1-6-alkoxy, C1-6-alkyl, C1-5-alkanoyl, C3-5-alkenyl, aryloxy, aralkoxy, amino, C1-6-alkyl mono or disubstituted amino, C1-4-alkanoylamino, carbamoyl, C1-4-alkyl N-mono or disubstituted carbamoyl, C1-4-alkyl substituted with amino, C1-2-alkyl mono or disubstituted amino, N0₂, morpholino or imidazolyl; and R is 3,4-methylenedioxyphenyl, aryl or heteroaryl all of which can be optionally substituted with one or more cyano, halogeno, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, trifluoromethyl, C3-5-alkylene, aryloxy, aralkoxy or C1-6-alkylthio; and R¹ and R² are C1-10-alkyl, C3-7-cycloalkyl, C2-10-alkenyl, C3-6-cycloalkyl-C1-5-alkyl, all of which can be unsubstituted or substituted with C1-5-alkyl, C1-5-alkoxy or cyano; or R¹ and R² together form a 5, 6 or 7 membered ring containing at least one nitrogen atom, or which optionally contains two nitrogen atoms, one or two oxygen atom(s) or one or two sulphur atom(s) or a combination thereof, which ring is unsubstituted or optionally substituted with C1-4-alkyl, C1-4-alkoxy or aryl; and R³, R⁴, R⁵, R⁶, and R⁷ independently are hydrogen, C1-4-alkyl or phenyl; or R⁴ and X together form a carbocyclic ring containing 5 or 6 atoms, or a salt thereof with a pharmaceutically acceptable acid; provided however that R¹ and R² are not C3-7-cycloalkyl, C1-10-alkyl or C2-10-alkenyl which may be straight, branched or cyclic, unsubstituted or substituted with C1-4-alkoxy, aryloxy or cycloalkyl, cyano or cycloalkylalkyl, when X is phenyl substituted with cyano, halogen, halogenalkyl, C1-6-alkoxy, C1-6-alkyl, C1-5-alkanoyl, C3-5-alkylene, aryloxy or aralkoxy, are useful in the treatment of anoxia, traumatic injury, ischemia, migraine, epilepsy, Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.

  化合物的公式I，其中X是苯基，未取代或可选地取代一个或多个氰基，卤基，卤代烷基，C1-6-烷氧基，C1-6-烷基，C1-5-酰基，C3-5-烯基，芳氧基，芳基氧基，氨基，C1-6-烷基单取代或双取代氨基，C1-4-酰胺基，氨基甲酰基，C1-4-烷基N-单取代或双取代的氨基甲酰基，C1-4-烷基取代氨基，C1-2-烷基单取代或双取代氨基，N0₂，吗啉基或咪唑基；以及R是3,4-亚甲二氧基苯基，芳基或杂环芳基，所有这些都可以可选地取代一个或多个氰基，卤基，C1-6-烷基，C1-6-烷氧基，C2-6-烯基，三氟甲基，C3-5-亚烷基，芳基氧基，芳基氧基或C1-6-烷硫基；以及R¹和R²是C1-10-烷基，C3-7-环烷基，C2-10-烯基，C3-6-环烷基-C1-5-烷基，所有这些都可以未取代或取代C1-5-烷基，C1-5-烷氧基或氰基；或R¹和R²一起形成一个含有至少一个氮原子的5、6或7元环，或可选地含有两个氮原子，一个或两个氧原子或一个或两个硫原子或其组合，该环未取代或可选地取代C1-4-烷基，C1-4-烷氧基或芳基；以及R³、R⁴、R⁵、R⁶和R⁷分别是氢，C1-4-烷基或苯基；或者R⁴和X一起形成一个含有5或6个原子的碳环，或其与药学上可接受的酸的盐；但是，当X是取代有氰基，卤基，卤代烷基，C1-6-烷氧基，C1-6-烷基，C1-5-酰基，C3-5-亚烷基，芳氧基或芳基氧基时，R¹和R²不是C3-7-环烷基，C1-10-烷基或C2-10-烯基，可以是直链，支链或环状，未取代或取代有C1-4-烷氧基，芳氧基或环烷基，氰基或环烷基烷基。这些化合物在缺氧，创伤性损伤，缺血，偏头痛，癫痫，帕金森病，阿尔茨海默病和其他神经退行性疾病的治疗中是有用的。